NCT04511130 Phase 2 Terminated
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Study sponsor: Marker Therapeutics, Inc. · MRKR
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source history conflict The current registry record and the imported research history disagree. Conflicting historical edits are excluded from this timeline, exports and sponsor statistics while the discrepancy is investigated. The summary below follows the current registry source.
Imported research includes version dates later than the current official API record (2025-10-30). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Inspect current registry record Changes Study details Primary completion 2024-03-01 Actual
Enrollment · participants 92 Actual
Source updated 2025-10-30 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-28 · 2 fields changed
Actual enrollment increased by 45 participants
− Before 47 participants (actual)
+ After 92 participants (actual)
Recruitment status changed
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial